GLPG Galapagos

    Mechelen, Belgium;  10 April  2007 -  Galapagos NV  (Euronext &  LSE:
GLPG) announced  today  that it  has  issued 628,058  new  shares  in
relation to the Inpharmatica acquisition and a warrant exercise.

On 6 December 2006, Galapagos  announced the acquisition of  UK-based
Inpharmatica Ltd.  Under the acquisition agreement, the  shareholders
of Inpharmatica have  contributed their  C Preference  shares to  the
capital of Galapagos, in exchange for a maximum of 2,165,532 newly to
be issued Galapagos  shares.   A first tranche  of 623,582  Galapagos
shares was  issued to  former Inpharmatica  shareholders in  December
2006 as consideration  for the contribution  of their shares.   On  6
April 2007,  a second  tranche of  613,270 new  Galapagos shares  was
issued and  allocated  to  the former  Inpharmatica  shareholders  as
further  consideration.     A   commercial  milestone   relating   to
Inpharmatica's business, that  was anticipated for  Q1 2007 and  that
would have significantly increased the number of Galapagos shares  to
be issued in further consideration, was not achieved by  Inpharmatica
at the agreed upon  due date; hence, no  Galapagos shares need to  be
issued in connection with this milestone, reducing the total purchase
price of Inpharmatica with 815,302 Galapagos shares.  A third tranche
of a maximum of 113,378 Galapagos shares is expected to be issued  on
7 May 2007 as final part of the consideration for the acquisition  of
Inpharmatica.   The newly  issued shares  are subject  to a  lock  up
agreement ending 10 May 2007.

On 4 April 2007, a total of 14,788 new shares were issued as a result
of the exercise of warrants by  (ex-) employees of Galapagos and  its
Dutch affiliate,  which  were granted  under  the Warrant  Plan  2002
Belgium and the Warrant Plan 2002 The Netherlands.

As a result  of both share  issues, the number  of Galapagos'  shares
outstanding as of 6 April  2007 is 20,479,388 shares, representing  a
share capital of �111,256,659.15.  All newly issued shares rank  pari
passu with Galapagos' existing shares.

About Galapagos

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone  and joint  diseases, cachexia,  and menopausal  hot
flashes.    Its  division  BioFocus  DPI  offers  a  full  suite   of
target-to-drug discovery products and services to pharmaceutical  and
biotech companies,  encompassing  target  discovery  and  validation,
screening and  drug discovery  through  to delivery  of  pre-clinical
candidates.  BioFocus DPI also provides adenoviral reagents for rapid
identification  and  validation  of  novel  drug  targets,   compound
libraries for drug  screening as well  as chemogenomics and  ADMET[1]
database  products  to  select  targets  and  compounds.    Galapagos
currently  employs  450  people  and  operates  facilities  in  eight
countries, with  global  headquarters  in Mechelen,  Belgium.    More
information  about  Galapagos  and  BioFocus  DPI  can  be  found  at
www.glpg.com.

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.






Copyright � Hugin ASA 2007. All rights reserved.

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024